Nuvectis Pharma
NVCT
33 hedge funds and large institutions have $20M invested in Nuvectis Pharma in 2025 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 3 reducing their positions, and 8 closing their positions.
333% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 3
181% more capital invested
Capital invested by funds: $7.15M → $20M (+$12.9M)
45% more call options, than puts
Call options by funds: $1.3M | Put options by funds: $895K
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
6% more funds holding
Funds holding: 31 → 33 (+2)
1.92% more ownership
Funds ownership: 6.84% → 8.75% (+1.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$1.83M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.02M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$784K |
| 4 |
Millennium Management
New York
|
+$658K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$404K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$617K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$328K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$166K |
| 4 |
Squarepoint
New York
|
-$58K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$34.1K |
NVCT Hedge Fund Activity: Q1 2025 in Review
33 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Nuvectis Pharma (NVCT) for Q1 2025, worth a combined $20M — up 181% from $7.15M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new NVCT positions and 8 closed out — a net gain of 2 holders — while 13 added to existing stakes and 3 trimmed.
The largest buyer was Iridian Asset Management, opening a new position worth an estimated $1.83M. The largest seller was Marshall Wace, cutting an estimated $617K.
- 33 institutional investors held Nuvectis Pharma (NVCT) as of Q1 2025, up from 31 in Q4 2024.
- Funds reported $20M of Nuvectis Pharma stock for Q1 2025, up 181% quarter-over-quarter.
- 10 funds opened new Nuvectis Pharma positions in Q1 2025 and 8 closed out, a net change of +2 holders.
- The largest Nuvectis Pharma buyer in Q1 2025 was Iridian Asset Management, an estimated $1.83M added.
- The largest Nuvectis Pharma seller in Q1 2025 was Marshall Wace, an estimated $617K sold.
Based on aggregated 13F filings for Q1 2025.